Latest News
Celcuity Inc.
- Celcuity reports phase 1b prostate cancer trial results By Investing.com
- Celcuity Inc. Estimates – NASDAQ:CELC
- Cantor sees ‘credible path to multi-billion-dollar peak sales’ for Celcuity
- Cantor Fitzgerald initiates Celcuity stock with overweight rating By Investing.com
- Citizens reiterates Celcuity stock rating on ESMO data presentation By Investing.com
- Citizens reiterates Celcuity stock rating on ESMO data presentation By Investing.com
- Celcuity to present gedatolisib trial data at ESMO congress By Investing.com
- Celcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026
- Celcuity appoints David W. Gryska as director and Audit & Compensation committee member
- Celcuity appoints David Gryska to board of directors By Investing.com
- Why Celcuity Stock Was a Winner on Wednesday
- Celcuity Announces That REVTORPYK™ (gedatolisib) Is Now Commercially Available In The United States
Headlines from the last 30 days, linking to the original publishers. See all market news →